Back to top

crispr: Archive

Zacks Equity Research

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.

ANIPPositive Net Change CTMXPositive Net Change ALLOPositive Net Change ETNBPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

BMRNPositive Net Change GILDPositive Net Change VRTXPositive Net Change EDITPositive Net Change